Media coverage about PetMed Express (NASDAQ:PETS) has been trending somewhat positive on Monday, Accern Sentiment Analysis reports. Accern identifies negative and positive press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. PetMed Express earned a news sentiment score of 0.19 on Accern’s scale. Accern also gave news headlines about the company an impact score of 46.3550754707094 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the media stories that may have impacted Accern Sentiment’s scoring:
- Bio-Rad (BIO) at a 52-Week High: What’s Driving the Stock? – Yahoo Finance (finance.yahoo.com)
- Boston Scientific (BSX) Shares Drop on LOTUS Relaunch Delay – Nasdaq (nasdaq.com)
- PetMed Express, Inc. (PETS) Receives Consensus Rating of “Hold” from Analysts (americanbankingnews.com)
- Here’s Why You Should Invest in Baxter (BAX) Stock Right Now (zacks.com)
PETS has been the topic of several recent research reports. ValuEngine upgraded shares of PetMed Express from a “hold” rating to a “buy” rating in a report on Friday, September 1st. Sidoti upgraded shares of PetMed Express from a “neutral” rating to a “buy” rating and set a $47.00 price target on the stock in a research note on Thursday, August 24th. BidaskClub lowered shares of PetMed Express from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, August 22nd. Zacks Investment Research downgraded PetMed Express from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 25th. Finally, Craig Hallum reissued a “hold” rating and set a $40.00 price objective (down from $43.00) on shares of PetMed Express in a research report on Monday, August 21st. They noted that the move was a valuation call. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and three have given a buy rating to the stock. PetMed Express has a consensus rating of “Hold” and an average price target of $42.00.
PetMed Express (NASDAQ:PETS) last released its quarterly earnings data on Monday, October 23rd. The company reported $0.43 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.30 by $0.13. The firm had revenue of $66.70 million during the quarter, compared to analysts’ expectations of $63.41 million. PetMed Express had a return on equity of 31.46% and a net margin of 11.58%. PetMed Express’s revenue was up 9.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.24 earnings per share. research analysts anticipate that PetMed Express will post 1.67 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which was paid on Friday, November 17th. Stockholders of record on Monday, November 6th were given a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a dividend yield of 2.03%. The ex-dividend date was Friday, November 3rd. PetMed Express’s dividend payout ratio is currently 53.69%.
In related news, Director Ronald J. Korn sold 1,000 shares of the stock in a transaction on Friday, October 27th. The stock was sold at an average price of $35.57, for a total transaction of $35,570.00. Following the sale, the director now owns 73,833 shares of the company’s stock, valued at $2,626,239.81. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 4.00% of the stock is owned by company insiders.
COPYRIGHT VIOLATION WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Affect PetMed Express (NASDAQ:PETS) Share Price” was reported by Week Herald and is the property of of Week Herald. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://weekherald.com/2017/12/04/petmed-express-pets-getting-somewhat-favorable-news-coverage-report-finds.html.
PetMed Express Company Profile
PetMed Express, Inc (PetMed Express), doing business as 1800PetMeds, is a pet pharmacy. The Company markets prescription and non-prescription pet medications, and other health products for dogs and cats, direct to the consumer. It offers a selection of products for dogs and cats. Its product line contains approximately 3,000 stock keeping units (SKUS) of pet medications, health products and supplies.
Receive News & Ratings for PetMed Express Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetMed Express Inc. and related companies with MarketBeat.com's FREE daily email newsletter.